BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+/HER2- breast cancer.